F. Hoffmann-La Roche AG — Sponsor Intelligence | 220 EU Trials

Filter these 220 trials by condition, phase, country and more.

Open in Search →

220 Registered trials

59 Recruiting

159 Completed trials

27 Countries active

157 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 92 Phase II/III: 6 Phase II: 45 Phase I/II: 18 Phase III/IV: 1 Phase IV: 4 Phase I: 16 Phase I (Other): 35 Phase I (FiH): 3

Oversight events:

7 serious breaches 23 temporary halts 7 urgent safety measures 11 unexpected events 6 corrective measures across 33 trials

View oversight register →

100%

159 of 159 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Multiple sclerosis 13 Non-small cell lung cancer 11 Obesity 10 Parkinson's disease 5 Non-small cell lung cancer metastatic 5 Overweight 5 Spinal muscular atrophy 5 HER2 positive breast cancer 5 Relapsing-remitting multiple sclerosis 5 Systemic lupus erythematosus 4 Breast cancer 4 Diffuse large B-cell lymphoma 4

Top IMPs

ATEZOLIZUMAB 29 OCRELIZUMAB 16 TOCILIZUMAB 15 TIRAGOLUMAB 13 INAVOLISIB 12 OBINUTUZUMAB 12 BEVACIZUMAB 8 RO7790121 8 RITUXIMAB 7 ALECTINIB 6 CROVALIMAB 6 DIPHENHYDRAMINE HYDROCHLORIDE 6

All trials

220 total

A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors Not authorised

2023-503170-20-00 Phase I 4 countries
A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman… Not authorised

2023-507633-21-00 Phase III 3 countries OCRELIZUMAB
QIMPD SUBMISSION ONLY Not authorised

2023-509510-11-00 Phase III 1 country MOSUNETUZUMAB
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD) Pending

2025-520631-17-00 Phase I 6 countries
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic effects of Subcutaneous Ocrelizumab in Childr… Pending

2025-524164-37-00 Phase II 3 countries OCRELIZUMAB
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting

2025-522434-32-00 Phase III 9 countries HUMANISED IGG4 MONOCLONAL ANTIBODY AGAINST FIXA AND FX
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Recruiting

2025-523579-47-00 Phase II 7 countries RO7790121
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting

2025-522435-33-00 Phase III 11 countries EMICIZUMAB; HUMANISED IGG4 MONOCLONAL ANTIBODY AGAINST FIXA AND FX
An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzyme… Recruiting

2025-524060-38-00 Phase I (Other) 3 countries
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Phase II/III 11 countries (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIF…
A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2025-521327-67-00 Phase II 4 countries INAVOLISIB
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting

2024-519622-20-00 Phase I 6 countries
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or… Recruiting

2025-521034-28-00 Phase II 7 countries RO7790121
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Phase III 6 countries FLORBETABEN (18F); FLORBETAPIR (18F); FLORQUINITAU (18F); FLUTEMETAMOL (18F); TR…
A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting

2024-515622-80-00 Phase III 8 countries EFMOROCTOCOG ALFA; EMICIZUMAB; EPTACOG ALFA (ACTIVATED); FACTOR VIII INHIBITOR B…
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the… Recruiting

2024-511239-91-00 Phase II 8 countries ALECTINIB; CARBOPLATIN; CISPLATIN; PEMETREXED
A Study to see how safe is RO7567132 as Single Agent and in Combination with Atezolizumab, how the body gets rid of it and how effective it … Recruiting

2024-512839-70-00 Phase I 4 countries
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N… Recruiting

2023-503920-14-00 Phase III 9 countries ALECTINIB; DURVALUMAB
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c… Recruiting

2023-504265-23-00 Phase II 11 countries PF-06480605; RO7790121
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting

2023-505140-19-00 Phase III 6 countries MYCOPHENOLATE MOFETIL; OBINUTUZUMAB
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm… Recruiting

2023-504226-18-00 Phase III 8 countries
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patie… Recruiting

2022-501876-24-00 Phase I (Other) 5 countries
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquapo… Recruiting

2023-507817-85-00 Phase III 3 countries SATRALIZUMAB
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Recruiting

2023-505638-82-00 Phase III 6 countries CROVALIMAB

Showing 1–24 of 220 trials

← All sponsors A–Z